TC Biopharm (Holdings) Plc (NASDAQ:TCBP) Short Interest Down 98.8% in January

TC Biopharm (Holdings) Plc (NASDAQ:TCBP) saw a large decrease in short interest during the month of January. As of January 31st, there was short interest totalling 3,800 shares, a decrease of 98.8% from the January 15th total of 318,300 shares. Based on an average trading volume of 104,400 shares, the days-to-cover ratio is currently 0.0 days.

Analyst Upgrades and Downgrades

Separately, HC Wainwright decreased their price objective on TC Biopharm from $112.00 to $48.00 and set a “buy” rating for the company in a report on Friday, December 6th.

TC Biopharm Price Performance

Shares of TCBP traded up $0.34 during trading hours on Wednesday, reaching $3.56. 204,502 shares of the company traded hands, compared to its average volume of 66,589. TC Biopharm has a 12-month low of $3.18 and a 12-month high of $523.20. The business has a fifty day moving average price of $8.33 and a 200-day moving average price of $44.71.

TC Biopharm Company Profile

TC Biopharm (Holdings) Plc, a clinical-stage biopharmaceutical company, focuses on the development of immunotherapy products based on its allogeneic gamma delta T cell platform. Its product pipeline includes OmnImmune, an allogeneic unmodified gamma-delta T cell therapy product under Phase 2/3 trails for the treatment of acute myeloid leukemia; and ImmuniStim, an unmodified cell therapy to treat viral infections as well as cancers.